Target Name: GAGE1
NCBI ID: G2543
Review Report on GAGE1 Target / Biomarker Content of Review Report on GAGE1 Target / Biomarker
GAGE1
Other Name(s): CT4.4 | Cancer/testis antigen 4.4 | CT4.1 | GAGE-4 | GAGE4 | Cancer/testis antigen 4.1 | MGC33825 | GAGE-1 | G antigen 1, transcript variant 1 | G antigen 1 (isoform 1) | cancer/testis antigen 4.1 | G antigen 4 | Cancer/testis antigen family 4, member 1 | OTTHUMP00000025848 | G antigen 1 | GAGE1 variant 1 | MZ2-F antigen | cancer/testis antigen family 4, member 1 | Antigen MZ2-F

Study: GAGE1's Role in Cellular Processes and Its Potential as A Drug Target

GAGE1 (Growth arrest and DNA damage-inducible gene 1) is a gene that has been identified as a potential drug target or biomarker for a variety of diseases, including cancer. Its unique function and regulation have made it an attractive target for researchers to study , and recent studies have shed new light on its role in various biological processes.

GAGE1 is a non-coding RNA molecule that is expressed in a variety of tissues and cells throughout the body. It is a key regulator of the cell cycle, responsible for regulating the growth and division of cells. GAGE1 has been shown to play a crucial role in the regulation of cell growth, as well as the onset of various diseases, including cancer.

One of the most significant functions of GAGE1 is its ability to induce cell cycle arrest in response to various stressors, such as chemotherapy drugs or radiation. This is important because cell cycle arrest is a critical checkpoint in the cell cycle that helps prevent the uncontrolled growth and division that can lead to the development of cancer. By inducing cell cycle arrest, GAGE1 can inhibit the growth and proliferation of cancer cells, making it a potential drug target or biomarker.

In addition to its role in cell cycle regulation, GAGE1 has also been shown to be involved in a variety of other biological processes. For example, GAGE1 has been shown to play a role in the regulation of gene expression, and has been shown to interact with a variety of proteins, including the oncogene p53. p53 is a well-known tumor suppressor gene that is often mutated in cancer, and GAGE1 has been shown to help regulate its activity.

Another function of GAGE1 is its ability to act as a negative regulator of the apoptosis pathway, which is a process that helps ensure the elimination of damaged or dysfunctional cells. GAGE1 has been shown to help regulate the apoptosis pathway in various ways, including by activating the B-cell lymphoma 1 (Bcl-1) gene, which is a known inhibitor of apoptosis.

GAGE1 has also been shown to play a role in the regulation of cellular immigration, which is the process by which cells move into and out of various tissues and organs. GAGE1 has also been shown to regulate the movement of cells into the bloodstream, which is an important step in the immune response and the delivery of vaccines.

In conclusion, GAGE1 is a gene that has a wide range of functions and has been shown to be involved in a variety of biological processes. Its unique regulation of the cell cycle and its involvement in the regulation of cell growth, apoptosis, and cellular immigration make it an attractive target for drug development. Further research is needed to fully understand the role of GAGE1 in various diseases, including cancer.

Protein Name: G Antigen 1

Functions: Antigen, recognized on melanoma by autologous cytolytic T-lymphocytes

The "GAGE1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GAGE1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GAGE10 | GAGE12B | GAGE12C | GAGE12D | GAGE12F | GAGE12G | GAGE12H | GAGE12J | GAGE2A | GAGE2B | GAGE2C | GAGE2D | GAGE4 | GAGE5 | GAGE6 | GAGE7 | GAGE8 | GAK | GAL | GAL3ST1 | GAL3ST2 | GAL3ST3 | GAL3ST4 | Galanin receptor | GALC | GALE | GALK1 | GALK2 | GALM | GALNS | GALNT1 | GALNT10 | GALNT11 | GALNT12 | GALNT13 | GALNT13-AS1 | GALNT14 | GALNT15 | GALNT16 | GALNT17 | GALNT18 | GALNT2 | GALNT3 | GALNT4 | GALNT5 | GALNT6 | GALNT7 | GALNT7-DT | GALNT8 | GALNT9 | GALNT9-AS1 | GALNTL5 | GALNTL6 | GALP | GALR1 | GALR2 | GALR3 | GALT | Gamma Crystallin | Gamma-Aminobutyric acid type B receptor | Gamma-aminobutyric-acid A receptor, Rho | gamma-delta T Cell Receptor (TCR) Complex | Gamma-glutamyl transferase | gamma-Secretase | Gamma-tubulin complex | GAMT | GAN | GANAB | GANC | Gap junction Connexin ( | Gap Junction Protein | GAP43 | GAPDH | GAPDHP1 | GAPDHP14 | GAPDHP21 | GAPDHP38 | GAPDHP42 | GAPDHP56 | GAPDHP62 | GAPDHP65 | GAPDHP72 | GAPDHS | GAPLINC | GAPT | GAPVD1 | GAR1 | GAREM1 | GAREM2 | GARIN1A | GARIN1B | GARIN2 | GARIN3 | GARIN4 | GARIN5A | GARIN5B | GARIN6 | GARNL3 | GARRE1 | GARS1